Researchers at the University of Houston College of Optometry are advancing a novel therapeutic approach aimed at preventing vision loss due to corneal scarring, called “mini-dec,” which offers enhanced binding to both TGF-β1 and VEGFR2. These proteins are key drivers of scarring and neovascularization, respectively.

Mini-dec is designed to overcome the production challenges associated with natural decorin, which is a natural corneal protein that keeps the cornea clear and healthy. The modified protein is not only easier to manufacture but it is also formulated for topical delivery via eye drops.

When injured, the cornea often heals with fibrotic scarring and abnormal neovascularization, both of which can lead to irreversible vision impairment. “Unfortunately, there are few treatments for this, and in severe cases, patients need a corneal transplant,” Assistant Professor and project lead Tarsis G. Ferreira noted in a press release.

The National Institutes of Health provided Professor Ferreira a 5-year, $2.2 million grant to develop a treatment that targets the molecular mechanisms that are responsible for corneal scarring.

“We hope this new therapy could soon be used to treat eye injuries and surgeries, helping people heal without losing vision,” said Professor Ferreira. “The decorin-based drugs will be simple to use and have the potential for treating corneal injuries in the clinic.”